Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

First Wave BioPharma Inc (NASDAQ:FWBI) stock has more than doubled after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic insufficiency in cystic fibrosis patients. Topline results from the study are anticipated by mid-2023.

Portfolio Pulse from Vandana Singh

June 13, 2023 | 2:21 pm

In Tuesday's pre-market session, 12 health care stocks experienced significant price movements. Gainers included FWBI, YS, IBIO, SILO, PTE, and DERM, while losers were ZJYL, BIOR, LABP, NXTC, AIH, and AXDX.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 1:07 pm

On June 13th, high-impact movers include MANU with a 30% increase due to a rumored successful bid by Qataris to purchase Manchester United, FWBI with a 134% increase after reaching enrollment target for Phase 2 clinical trial in cystic fibrosis, and OLB with a 112% increase ahead of their presentation at the Emerging Growth Conference on June 14.

Portfolio Pulse from ryanfaloona@benzinga.com

June 13, 2023 | 12:47 pm

First Wave Biopharma has achieved its enrollment target for the adrulipase Phase 2 SPAN trial, which focuses on exocrine pancreatic insufficiency in cystic fibrosis patients. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 11:15 am

First Wave Biopharma has reached its enrollment target for the Phase 2 SPAN trial of Adrulipase, an enhanced enteric microgranule delivery formulation for exocrine pancreatic insufficiency in cystic fibrosis patients. Top line data is expected in July 2023.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 11:04 am

The article highlights 5 value stocks in the healthcare sector, including Pfizer, First Wave BioPharma, Sensus Healthcare, Agile Therapeutics, and Revelation Biosciences. These companies have low P/E multiples, indicating they may be undervalued. However, investing in value stocks carries the risk that their undervalued position may not improve.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 2:44 pm

During Thursday's intraday session, several health care stocks experienced significant price movements. Gainers included ThermoGenesis Holdings, GT Biopharma, AcelRx Pharmaceuticals, CVRx, Navidea Biopharmaceutical, and LENSAR. Losers included Precipio, First Wave BioPharma, Kezar Life Sciences, Eloxx Pharmaceuticals, Coeptis Therapeutics, and PolarityTE.

Portfolio Pulse from Benzinga Insights

June 08, 2023 | 5:32 pm

On Wednesday, 29 companies set new 52-week lows, with NovoCure being the largest in terms of market cap and HTG Molecular Diagnostics being the smallest. PolarityTE's stock fell the most, while Owlet's shares rebounded the highest.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 4:38 pm

In Monday's pre-market session, several health care stocks experienced significant price movements. Elevation Oncology, eFFECTOR Therapeutics, Shuttle Pharmaceuticals, PDS Biotechnology, Arcus Biosciences, and First Wave BioPharma were among the gainers, while Tilray Brands, Evoke Pharma, Theseus Pharmaceuticals, TScan Therapeutics, Freeline Therapeutics, and Minerva Surgical were among the losers.

Portfolio Pulse from Benzinga Insights

May 29, 2023 | 1:06 pm

On Monday, 85 stocks hit new 52-week lows, with Bristol-Myers Squibb being the biggest company on a market cap basis to set a new low. Adamis Pharmaceuticals was the biggest loser, trading down 6320.0%, while Greystone Housing Impact shares were the most resilient, rising 0.0%.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 4:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.